Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850893 | 1.00 | MGAM (0.34) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL1144293 | 0.77 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1144274 | 0.77 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1144297 | 0.77 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8996580 | 0.77 | HCAR2 (0.40) | GAASMN1; SMN2TSHRKEAP1NFE2L2 | |
| SCHEMBL11683391 | 0.77 | HCAR2 (0.40) | GAASMN1; SMN2TSHRKEAP1NFE2L2 | |
| SCHEMBL15482658 | 0.76 | ACACB (0.41) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL12164763 | 0.72 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8972302 | 0.72 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL16367683 | 0.72 | TSHR (0.40) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100875-B1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-1685092-B1 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO PERFUMERY CO LTD (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-7626034-B2 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2100875-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | Takasago International Corporation (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1685092-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | AADAT, BCAT2, BCAT1 | MGAM 2287/4885GAA 3505/4885SI 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.